New Jersey-based Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic information services, offering a ...

Quest Diagnostics (NYSE:DGX) is partnering with Guardant Health to offer Shield, an FDA-approved blood test for colorectal cancer screening, across its nationwide network. The agreement expands access ...

Quest Diagnostics and Elevance Health are broadening their partnership into four more states with the goal of making it easier for patients to access in-network laboratory services. Beginning Jan. 1, ...

Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S. Starting in April, providers with a Quest account will be able to order ...

Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging ...

Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multilayered deal with PathAI—acquiring some assets and licensing out others. The testing ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

What Quest Diagnostics’ recent performance tells you Quest Diagnostics (DGX) has attracted fresh attention after recent share gains, with the stock up about 16% over the past month and roughly 12% ...

The deal expands the local firm’s footprint as Quest exits market. #NewsismyBusiness - Stay updated with the latest Puerto Rico business news, economy insights, finance, retail, tourism, and more from ...